AP2α controls the dynamic balance between miR-126&126∗ and miR-221&222 during melanoma progression

Oncogene

Volumn 35, Issue 23, 2016, Pages 3016-3026

  Felli, N ^a   Errico, M C ^a   Pedini, F ^a   Petrini, M ^a   Puglisi, R ^a   Bellenghi, M ^a   Boe, A ^a   Felicetti, F ^a   Mattia, G ^a   De Feo, A ^a   Bottero, L ^a   Tripodo, C ^b   Care A ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AP2 ALPHA TRANSCRIPTION FACTOR; DECITABINE; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; MICRORNA 126; MICRORNA 221; MICRORNA 222; TRANSCRIPTION FACTOR; TRICHOSTATIN A; UNCLASSIFIED DRUG; FABP4 PROTEIN, HUMAN; FATTY ACID BINDING PROTEIN; MICRORNA; MIRN126 MICRORNA, HUMAN; MIRN221 MICRORNA, HUMAN; MIRN222 MICRORNA, HUMAN;

ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; MELANOMA; METASTATIC MELANOMA; PRIORITY JOURNAL; PROMOTER REGION; PROMYELOCYTIC LEUKEMIA; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; TRANSCRIPTION REGULATION; TUMOR GROWTH; CELL DIFFERENTIATION; DISEASE COURSE; GENETICS; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

CELL DIFFERENTIATION; CELL LINE, TUMOR; DISEASE PROGRESSION; FATTY ACID-BINDING PROTEINS; HUMANS; MELANOMA; MICRORNAS;

EID: 84973888827     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2015.357     Document Type: Article

References (41)

1. Eggermont AMM, Spatz A, Robert C. Cutaneous melanoma. Lancet 2014; 383: 816-827.
2. Little EG, Eide MJ. Update on the current state of melanoma incidence. Dermatol Clin 2012; 30: 355-361.
3. Kwong LN, Davies MA. Targeted therapy for melanoma: rational combinatorial approaches. Oncogene 2014; 33: 1-9.
4. Das Thakur M, Stuart DD. The evolution of melanoma resistance reveals therapeutic opportunities. Cancer Res 2013; 73: 6106-6110.
5. Menzies AM, Long GV. Systemic treatment for BRAF-mutant melanoma: where do we go next? Lancet Oncol 2014; 15: E371-E381.
6. Aftab MN, Dinger ME, Perera RJ. The role of microRNAs and long non-coding RNAs in the pathology, diagnosis, and management of melanoma. Arch Biochem Biophys 2014; 563: 60-70.
7. Dai X, Tan C. Combination of microRNA therapeutics with small-molecule anticancer drugs: mechanism of action and co-delivery nanocarriers. Adv Drug Deliv Rev 2015; 81: 184-197.
8. Felicetti F, Errico MC, Bottero L, Segnalini P, Stoppacciaro A, Biffoni M et al. The promyelocytic leukemia zinc finger-microRNA-221/-222 pathway controls melanoma progression through multiple oncogenic mechanisms. Cancer Res 2008; 68: 2745-2754.
9. Felli N, Felicetti F, Lustri AM, Errico MC, Bottero L, Cannistraci A et al. miR-126&126∗restored expressions play a tumor suppressor role by directly regulating ADAM9 and MMP7 in melanoma. PLoS One 2013; 8: e56824.
10. Garofalo M, Quintavalle C, Romano G, Croce CM, Condorelli G. miR221/222 in cancer: their role in tumor progression and response to therapy. Curr Mol Med 2012; 12: 27-33.
11. Ebrahimi F, Gopalan V, Smith RA, Lam AK. miR-126 in human cancers: clinical roles and current perspectives. Exp Mol Pathol 2014; 96: 98-107.
12. Mattia G, Errico MC, Felicetti F, Petrini M, Bottero L, Tomasello L et al. Constitutive activation of the ETS-1-miR-222 circuitry in metastatic melanoma. Pigment Cell Melanoma Res 2011; 24: 953-965.
13. Izumi Y, Hirata M, Hasuwa H, Iwamoto R, Umata T, Miyado K et al. A metalloprotease-disintegrin, MDC9/meltrin-gamma/ADAM9 and PKC delta are involved in TPA-induced ectodomain shedding of membrane-anchored heparinbinding EGF-like growth factor. EMBO J 1998; 17: 7260-7272.
14. Kivisaari AK, Kallajoki M, Ala-aho R, McGrath JA, Bauer JW, Konigova R et al. Matrix metalloproteinase-7 activates heparin-binding epidermal growth factor-like growth factor in cutaneous squamous cell carcinoma. Br J Dermatol 2010; 163: 726-735.
15. Toki F, Nanba D, Matsuura N, Higashiyama S. Ectodomain shedding of membraneanchored heparin-binding EGF like growth factor and subcellular localization of the Cc-terminal fragment in the cell cycle. J Cell Physiol 2005; 202: 839-848.
16. Nanba D, Mammoto A, Hashimoto K, Higashiyama S. Proteolytic release of the carboxy-terminal fragment of proHB-EGF causes nuclear export of PLZF. J Cell Biol 2003; 163: 489-502.
17. Felicetti F, Bottero L, Felli N, Mattia G, Labbaye C, Alvino E et al. Role of PLZF in melanoma progression. Oncogene 2004; 23: 4567-4576.
18. Wang J, Bai Y, Li H, Greene SB, Klysik E, Yu W et al. MicroRNA-17-92, a direct Ap-2alpha transcriptional target, modulates T-box factor activity in orofacial clefting. PLoS Genet 2013; 9: e1003785.
19. Mobley AK, Braeuer RR, Kamiya T, Shoshan E, Bar-Eli M. Driving transcriptional regulators in melanoma metastasis. Cancer Metastasis Rev 2012; 31: 621-632.
20. Bar-Eli M. Gene regulation in melanoma progression by the AP-2 transcription factor. Pigment Cell Res 2001; 14: 78-85.
21. Melnikova VO, Bar-Eli M. Transcriptional control of the melanoma malignant phenotype. Cancer Biol Ther 2008; 7: 997-1003.
22. Baldi A, Santini D, Battista T, Dragonetti E, Ferranti G, Petitti T et al. Expression of AP-2 transcription factor and of its downstream target genes c-kit, E-cadherin and p21 in human cutaneous melanoma. J Cell Biochem 2001; 83: 364-372.
23. Kim YK, Kim VN. Processing of intronic microRNAs. EMBO J 2007; 26: 775-783.
24. Liu R, Gu J, Jiang P, Zheng Y, Liu X, Jiang X et al. DNMT1-MicroRNA126 Epigenetic circuit contributes to esophageal squamous cell carcinoma growth via ADAM9-EGFR-AKT signaling. Clin Cancer Res 2015; 21: 854-863.
25. Saito Y, Friedman JM, Chihara Y, Egger G, Chuang JC, Liang G. Epigenetic therapy upregulates the tumor suppressor microRNA-126 and its host gene EGFL7 in human cancer cells. Biochem Biophys Res Commun 2009; 379: 726-731.
26. Zhang Y, Yang P, Sun T, Li D, Xu X, Rui Y et al. miR-126 and miR-126∗ repress recruitment of mesenchymal stem cells and inflammatory monocytes to inhibit breast cancer metastasis. Nat Cell Biol 2013; 15: 284-294.
27. Alcazar O, Achberger S, Aldrich W, Hu Z, Negrotto S, Saunthararajah Y et al. Epigenetic regulation by decitabine of melanoma differentiation in vitro and in vivo. Int J Cancer 2012; 131: 18-29.
28. Le Bras A, Samson C, Trentini M, Caetano B, Lelievre E, Mattot V et al. VE-statin/ egfl7 expression in endothelial cells is regulated by a distal enhancer and a proximal promoter under the direct control of Erg and GATA-2. PLoS One 2010; 5: e12156.
29. Du C, Lv Z, Cao L, Ding C, Gyabaah OA, Xie H et al. MiR-126-3p suppresses tumor metastasis and angiogenesis of hepatocellular carcinoma by targeting LRP6 and PIK3R2. J Transl Med 2014; 12: 259.
30. Yang X, Wu H, Ling T. Suppressive effect of microRNA-126 on oral squamous cell carcinoma in vitro. Mol Med Rep 2014; 10: 125-130.
31. Ozeki K, Tanida S, Morimoto C, Inoue Y, Mizoshita T, Tsukamoto H et al. Telmisartan inhibits cell proliferation by blocking nuclear translocation of ProHB-EGF C-terminal fragment in colon cancer cells. PLoS One 2013; 8: e56770.
32. Xu M, Chen X, Chen N, Nie L, Li X, Li Q et al. Synergistic silencing by promoter methylation and reduced AP-2alpha transactivation of the proapoptotic HRK gene confers apoptosis resistance and enhanced tumor growth. Am J Pathol 2013; 182: 84-95.
33. Braeuer RR, Zigler M, Villares GJ, Dobroff AS, Bar-Eli M. Transcriptional control of melanoma metastasis: the importance of the tumor microenvironment. Semin Cancer Biol 2011; 21: 83-88.
34. Jonckheere N, Fauquette V, Stechly L, Saint-Laurent N, Aubert S, Susini C et al. Tumour growth and resistance to gemcitabine of pancreatic cancer cells are decreased by AP-2alpha overexpression. Br J Cancer 2009; 101: 637-644.
35. Igoucheva O, Alexeev V. MicroRNA-dependent regulation of cKit in cutaneous melanoma. Biochem Biophys Res Commun 2009; 379: 790-794.
36. Meister J, Schmidt MH. miR-126 and miR-126∗: new players in cancer. ScientificWorldJournal 2010; 10: 2090-2100.
37. Fish JE, Santoro MM, Morton SU, Yu SH, Yeh RF, Wythe JD et al. MiR-126 regulates angiogenic signaling and vascular integrity. Dev Cell 2008; 15: 272-284.
38. Sun Y, Bai Y, Zhang F, Wang Y, Guo Y, Guo L. miR-126 inhibits non-small cell lung cancer cells proliferation by targeting EGFL7. Biochem Biophys Res Commun 2010; 391: 1483-1489.
39. Hallberg AR, Vorrink SU, Hudachek DR, Cramer-Morales K, Milhem MM, Cornell RA et al. Aberrant CpG methylation of the TFAP2A gene constitutes a mechanism for loss of TFAP2A expression in human metastatic melanoma. Epigenetics 2014; 9: 1641-1647.
40. Errico MC, Felicetti F, Bottero L, Mattia G, Boe A, Felli N et al. The abrogation of the HOXB7/PBX2 complex induces apoptosis in melanoma through the miR-221&222-c-FOS pathway. Int J Cancer 2013; 133: 879-892.
41. Li LC, Dahiya R. MethPrimer: designing primers for methylation PCRs. Bioinformatics 2002; 18: 1427-1431.